Versions Compared

Key

  • This line was added.
  • This line was removed.
  • Formatting was changed.
Comment: Migration of unmigrated content due to installation of a new plugin
Today's To Do
 To do's:
  •  pour kan x-gal plates 
  •  restreak TRE:Syk-mRFP-(t)TEVp
  •  pick TRE:Syk-mRFP-(t)TEVp
  •  miniprep digest verify TRE:Syk-mRFP-(t)TEVp
  •  transform pENTR LacI and pENTR pLac
  •  pick hEF1a:LacI, TRE:mKate, pLac:mKate
  •  digest, gel hEF1a:LacI, TRE:mKate, pLac:mKate LR2
  •  miniprep TRE:gal4 transformation 2 
  •  digest, gel verify TRE gal4 transformation 2
  •  split cells 
  •  pLac:mKate pick colonies
  •  ScaI to lab stock
Geneious To Do List:
  •  

    SDM primers: CD79B, Gal4VP16, TEVp

  •  TRE:gal4vp16 sequencing primers
  •  TRE:Syk-mRFP-(t)TEVp sequening primers
  •  hef1a sequencing primers

 

  •  Midiprep (from freezer)
    •  S9TEV
    •  B15T15
  •  Golden Gate
    •  B9T9
    •  B15T9
  •  LR
    •  hEF1a-CuO:Gmab H
    •  hEF1a-CuO:Gmab L
    •  hEF1a-CuO:CD79A
    •  hEF1a-CuO:CD79B
    •  hEF1a-CuO:Lyn
  •  Digest all of the Syk-TEVp and Syk-tTEVp midis just to be sure (since there's an internal cut site that didn't get read in sequencing)



Sequencing account information:BCR 2.0 To Do
^^^Email: bcrpeeps@mit.edu

^^^Pass: grapefruit

 

 

## Digest tTEVp and TEVp midis just to be sure (since there's an internal cut site)

Non-Lab To Do's 
  •  Bug Brian about ordering antibody testing supplies
Higher Level To Do's:
  •  Decide on other antigen-variable regions we want to test  
  •  Other experimental planning (on experimental page)
  •  Parts list (excel sheet detailing specs/locations of parts)
  •  How do we do site directed mutagenesis?
  •  Literature research: 
    •  kozak sequences for heavy and light chains and CD79s
    •  truncated TEVp
    •  other antigens to detect using BCR (we were thinking of small molecule detection)
    •  inducible promoters (we were considering LacI - an inducible repressor - but we want to look into other options first) 
  •  Cloning planning 
    •  hEF1a:Syk-pTet:mRFP-TEVp
    •  variable region 
  • Is gantenerumab proprietary and can we actually publish with it?